Blincyto’s approval was based on results from the Phase III E1910 clinical trial, which found a significant improvement in overall survival in CD19-positive Ph-negative B-cell ALL compared with chemotherapy alone.
Blincyto’s approval was based on results from the Phase III E1910 clinical trial, which found a significant improvement in overall survival in CD19-positive Ph-negative B-cell ALL compared with chemotherapy alone.
Sign in to your account